With tough Japanese enforcers eyeing its Blopress marketing, Takeda chief admits missteps

Japan's health ministry is one of the world's toughest when it comes to demanding truth in advertising. Violators can be thrown in prison. And the newest target of its scrutiny is Takeda Pharmaceutical, which is now admitting it may have mismarketed its hypertension drug Blopress. Takeda's CEO, Yasuchika Hasegawa, said this week that the company used "inappropriate expressions" to advertise the drug, according to The Wall Street Journal. Report